 | • レポートコード：C-MOR-100385 • 出版社/出版日：Mordor Intelligence / 2019年8月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：製薬 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site License | ￥888,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、ナノエマルジョンの世界市場について調査・分析し、ナノエマルジョンの世界市場規模、市場動向、市場環境分析、市場展望、セグメント別分析、地域別分析、関連企業情報など以下の構成でお届け致します。 |
Market Overview
The Nanoemulsion market is anticipated to grow with a CAGR of 8.6% during the forecast period, 2019-2024.
Vaccines are believed to play a significant role in the treatment of several chronic diseases, which have become more prevalent in recent decades. There is an increasing number of biopharmaceutical companies being attracted to the use of nanoemulsion formulation in the development of the vaccine. The last decade has shown several promises, with successful results of nanoemulsion being used as adjuvants for vaccines, and treat chronic infections and cancer diseases through targeted therapies. Increasing research projects through institutes in collaboration with various government funds and companies are seen, which primarily deal with the improvement of the oral delivery of drugs for the management of chronic diseases. As per a 2017, article publication in P&T Community, several nano-drugs have been developed, which improved the efficacy of cancer immunotherapies by multiple times. The nanoemulsion has helped to manage the dose-limiting toxicities associated with the conventional chemotherapeutic agents. The nanoemulsion provides enhanced transdermal permeation of drugs, which in turn increases the plasma concentration profiles and bioavailability of the drug. In the case of cancer indications, the nanoemulsion and nanoparticle form helps in higher cancer cell killing potential and better treatment of cancer, osteoarthritis, fibromyalgia, among others. With the constant demand for new and improved vaccines, nanoemulsion applications are expected to rise, globally, and drive this market.
Scope of the Report
With the unique properties, such as small droplet size, the nanoemulsions make an attractive option for applications in the pharmaceuticals industry. It significantly improves the bioavailability of hydrophobic drugs, where its market is primarily driven by its stability and chemical properties, increasing the adoption of targeted therapies, and minimally invasive procedures.
Key Market Trends
Antibiotics are Expected to Grow with High CAGR in the Forecasted Period
There is a rising interest in the application of nanoemulsion in antimicrobial properties and be effective anti-biofilm agents. The rising antibiotic resistance has received increased attention from researchers and companies across the world, however, the rate of new antibiotics released in the market for therapeutic treatment against emerging “superbugs” has been low. There has been an increasing number of research articles on nanoemulsion over antibacterial properties, such as stability and antibacterial properties of erythromycin oil-in-water nanoemulsion against Staphylococcus aureus, Pseudomonas Aeruginosa, and Streptococcus pneumonia, published in Asian Journal of Pharmaceutical Education and Research, 2018. Further, Foamix marketed minocycline (Solodyn – brand name) is the standard of care for moderate to severe acne, for which the company has developed non-emulsion foam for drug delivery of minocycline topically (FMX101), for better effectiveness and lesser side effects. In addition, some other companies have also advanced its product in this segment to the later stages of clinical development, such as OCU300, by Ocugen to treat ocular discomfort and redness. It contains brimonidine tartrate formulated in a nanoemulsion. With applications in a wide range of antibiotics for several diseases and better treatment possibilities, the companies, which invest in this segment is steady. Thus, over the forecast period, the success rate and adoption may further determine the growth and challenges for this segment.
There is a rising interest in the application of nanoemulsion in antimicrobial properties and be effective anti-biofilm agents. The rising antibiotic resistance has received increased attention from researchers and companies across the world, however, the rate of new antibiotics released in the market for therapeutic treatment against emerging “superbugs” has been low. There has been an increasing number of research articles on nanoemulsion over antibacterial properties, such as stability and antibacterial properties of erythromycin oil-in-water nanoemulsion against staphylococcus aureus, pseudomonas aeruginosa, and streptococcus pneumonia, published in Asian Journal of Pharmaceutical Education and Research, 2018. Further, Foamix marketed minocycline (Solodyn – brand name) is the standard of care for moderate to severe acne, for which the company has developed non-emulsion foam for drug delivery of minocycline topically (FMX101), for better effectiveness and lesser side effects. In addition, some other companies have also advanced its product in this segment to the later stages of clinical development, such as OCU300, by Ocugen to treat ocular discomfort and redness. It contains brimonidine tartrate formulated in a nanoemulsion. With applications in a wide range of antibiotics for several diseases and better treatment possibilities, the companies, which invest in this segment is steady. Thus, over the forecast period, the success rate and adoption may further determine the growth and challenges for this segment.
North America is expected to dominate the overall market, throughout the forecast period. In North America region, the United States holds the largest market share and this is due to the increasing R&D on drug discovery and technological advancements in nanoemulsion vaccines and drugs which has helped the growth of the Nanoemulsion market in the country.
Competitive Landscape
The Nanoemulsion market is competitive and consists of a few major players and many small players. In terms of market share, these major players currently dominate the market. Some of the major players of the market are Ascendia Pharmaceuticals, Covaris, Inc., Microfluidics (IDEX Corporation), Taiwan Liposome Company, Ltd., Allergan plc, are among others.
Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.
レポート目次1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Stability and Chemical Properties for Efficient Drug Delivery
4.2.2 Increasing Burden of Chronic Diseases and Development of Vaccines
4.2.3 Rising Adoption of Targeted Therapeutics and Image-Guided Therapies
4.3 Market Restraints
4.3.1 High Manufacturing Expenses and Technical Difficulties
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Anesthetics
5.1.2 Antibiotics
5.1.3 Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.1.4 Immunosuppressants
5.1.5 Steroids
5.1.6 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Others
5.3 By Distribution Channel
5.3.1 Hospital Chain
5.3.2 Retail Stores
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan plc
6.1.2 Ascendia Pharmaceuticals
6.1.3 Covaris, Inc.
6.1.4 Foamix Pharmaceuticals
6.1.5 Latitude Pharmaceuticals Inc.
6.1.6 Microfluidics (IDEX Corporation)
6.1.7 Mitsubishi Tanabe Pharma
6.1.8 Santen Pharmaceutical Co., Ltd
6.1.9 Taiwan Liposome Company, Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS